戻る Agenda
Population Diversity Considerations in Clinical Trials
Session Chair(s)
Freda Cooner, PhD
Statistician
FDA, United States
To promote health equity and reduce disparities in racial and ethnic minorities, this session will discuss potential trial designs and statistical methods to increase the participation of minorities and/or diversity of populations in clinical trials.
Learning Objective : Discuss considerations and strategies in clinical trials' planning and conduct to enhance population diversity; Describe statistical challenges in clinical trial subgroup disparities; Identify potential trial designs and methodologies to mitigate disparity factors in the patient population.
Speaker(s)
Considerations on the Use of Analytics and Technology to Enhance Diversity in Clinical Trials
Demissie Alemayehu, PhD
Pfizer Inc, United States
Vice President, Biostatistics
Disparities by Demographic Subgroups in Clinical Trials Submitted to the FDA
Laura Fernandes, PhD
COTA, United States
Senior Statistical Director
Panelist
Ruthie Davi, PhD, MS
Medidata, a Dassault Systèmes Company, United States
Vice President, Data Science and Statistician